onfasprodil subcutaneous (MIJ821 SC)
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
February 20, 2024
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
(clinicaltrials.gov)
- P2 | N=60 | Completed | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Completed
Trial completion • CNS Disorders • Depression • Mood Disorders • Psychiatry
April 24, 2023
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
(clinicaltrials.gov)
- P2 | N=56 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Sep 2023 ➔ Jan 2024 | Trial primary completion date: Aug 2023 ➔ Dec 2023
Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry
January 09, 2023
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
(clinicaltrials.gov)
- P2 | N=56 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Depression • Mood Disorders • Psychiatry
December 20, 2022
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
(clinicaltrials.gov)
- P2 | N=56 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Initiation date: Sep 2022 ➔ Jan 2023
Trial initiation date • CNS Disorders • Depression • Mood Disorders • Psychiatry
July 12, 2022
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
(clinicaltrials.gov)
- P2 | N=56 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P2 trial • CNS Disorders • Depression • Mood Disorders • Psychiatry
1 to 5
Of
5
Go to page
1